Clinical Trial VICCPED1186


CA180-372 / AALL1122 - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66, 971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Principal Investigator(s)

Kristen Snyder


  • Protocol No. VICCPED1186
  • Open Date: 06/11/2012
  • Staging: Phase II
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: Compare the 3-year event-free survival (EFS) with the external historical controls of the AIEOP-BFM 2000 and EsPhALL trials.
  • Disease Sites: Pediatrics; Leukemia; Pediatric Leukemia
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: 6-mercaptopurine (6-MP); 6-thioguanine (6-TG); Cyclophosphamide (CTX); Cytarabine (ARA-C); Dasatinib (BMS-354825); Daunorubicin (Daunomycin); Dexamethasone; Ifosfamide; L-Asparaginase; Leucovorin (Folinic acid); Methotrexate; Vincristine
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01460160
  • Secondary Protocol No: CA180372



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.